Patents Examined by Lance W Rider
  • Patent number: 11344627
    Abstract: Described herein are hybrid nanoparticles that are exosomes loaded with one or more nanoparticle dendrimers. Also included are pharmaceutical compositions including the hybrid nanoparticles and methods of making the hybrid nanoparticles. Also described is a method of treating a human subject by administering to the human subject the above-described hybrid nanoparticles.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 31, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Seungpyo Hong, Sin-Jung Park
  • Patent number: 11324837
    Abstract: Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 10, 2022
    Assignee: Portland State University
    Inventor: Marilyn Mackiewicz
  • Patent number: 11305024
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: April 19, 2022
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe William Gray
  • Patent number: 11266740
    Abstract: Nanoparticles having radially-oriented pores are fabricated from a noble metal. The pores have a specific geometrical shape, such as a circle, triangle, hexagon or other polygon. The nanoparticles are administered to a subject to form a nanoparticle-loaded tumor, which is targeted with a radiation beam as part of a radiotherapeutic treatment. The pores redirect photons of the radiation beam to intensify and enhance the dose received by tumor cells, while concomitantly reducing the dose received by surrounding cells and/or tissues. The nanoparticles may be combined with a radiosensitizing drug or agent, administered together or separately, to form a dose-enhancement composition that further intensifies the received dose of radiation at the target.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 8, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventor: Fouad Abdulaziz Abolaban
  • Patent number: 11246938
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 15, 2022
    Assignee: Baxter International Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Patent number: 11242314
    Abstract: The present disclosure relates to the methods for the preparation of reactive [F-18]fluoride in a form of [F-18]sulfonyl fluoride suitable for efficient radiolabeling without an azeotropic evaporation step by the use of anion exchange resin and sulfonyl chloride, and its applications in the manufacturing of PET radiopharmaceuticals.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: February 8, 2022
    Assignee: Washington University
    Inventors: Dong Zhou, Wenhua Chu
  • Patent number: 11224576
    Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: January 18, 2022
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus
  • Patent number: 11207428
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 28, 2021
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe Gray
  • Patent number: 11197826
    Abstract: Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 14, 2021
    Assignee: NOVARTIS AG
    Inventors: Ugo D'Oro, Luis Brito, Derek O'Hagan, Silvia Vendetti
  • Patent number: 11142633
    Abstract: An aqueous composition which is useful for producing coatings and capsule shells comprises a) dispersed particles of an esterified cellulose ether comprising (i) groups of the formula —C(O)—R—COOA or (ii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, wherein R is a divalent hydrocarbon group and A is hydrogen or a cation, and the total degree of ester substitution is more than 0.70, and b) an esterified cellulose ether comprising aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOH, R being a divalent hydrocarbon group, wherein I) the degree of neutralization of the groups —C(O)—R—COOH is not more than 0.4, II) the total degree of ester substitution is from 0.03 to 0.70, and III) the esterified cellulose ether b) has a solubility in water of at least 2.0 weight percent at 2° C.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: October 12, 2021
    Assignee: Nutrition & Biosciences USA 1, LLC
    Inventors: Oliver Petermann, Matthias Knarr, Meinolf Brackhagen
  • Patent number: 11135177
    Abstract: The subject invention relates to novel micoparticulate and soluble forms of flavonoids, and their synthesis. The invention also includes novel formulations of such flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: October 5, 2021
    Assignee: Vizuri Health Sciences Consumer Healthcare, Inc.
    Inventor: Philip J. Birbara
  • Patent number: 11135309
    Abstract: The present invention provides a nanoparticle including at least one poly(vinyl alcohol) (PVA) having a molecular weight of from about 10 kDa to about 200 kDa, substituted with one or more moieties selected from: a therapeutic agent having a boronic acid moiety, wherein the therapeutic agent is covalently linked to the PVA via a boronate ester bond; a crosslinking group having a disulfide moiety, wherein the crosslinking group is covalently linked to the PVA, and a porphyrin, wherein the porphyrin is covalently linked to the PVA. Use of the nanoparticles for tumor detection and the treatment of diseases, including methods for photodynamic therapy and photothermal therapy, are also described.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: October 5, 2021
    Assignee: The Regents of the University of California
    Inventors: Kit S. Lam, Yuanpei Li, Kai Xiao, Caihong Feng
  • Patent number: 11135156
    Abstract: A pharmaceutical tablet for use in administering one or more pharmaceutically active ingredients, comprising a polymer system, the one or more pharmaceutically active ingredients, a flavor, and a sweetener, wherein at least 20% by weight of the pharmaceutical tablet comprises substantially non-elastomeric polymer and less than 5% by weight of the pharmaceutical tablet comprises one or a combination of elastomeric polymers, and wherein the pharmaceutical tablet comprises at least 70% by weight of said polymer system comprising polyvinyl acetate (PVA) and less than 10% by weight of said polymer system comprising polymer having a molecular weight (Mw) greater than 50,000 g/mol.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 5, 2021
    Assignee: FERTIN PHARMA A/S
    Inventors: Martin Topsoe, Kirsten Lund
  • Patent number: 11097020
    Abstract: The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of therapeutic agents. In one embodiment, these compositions are used for the tumor-targeted delivery of chemotherapeutic agents useful for treating cancer.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: August 24, 2021
    Assignee: SIGNABLOK, INC.
    Inventor: Alexander B. Sigalov
  • Patent number: 11045559
    Abstract: The present invention relates to a nanocomposite for detecting hydrogen sulfide; a method for preparing the same; a novel reactive fluorogenic compound to be used in the method; a kit for detecting hydrogen sulfide comprising the nanocomposite; and a method for providing information for the diagnosis of a disease, which causes abnormal secretion of hydrogen sulfide, by using the nanocomposite.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 29, 2021
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sehoon Kim, Myung Kim, Young Hun Seo, Jungyun Heo, Youngsun Kim
  • Patent number: 10973933
    Abstract: Disclosed herein are nanoparticles for diagnosis or treatment of tumors. The nanoparticles include: (a) a core including a Prussian blue dye; and (b) a shell obtained by partially or completely coating a surface of the Prussian blue core with albumin, thereby diagnosing a tumor by a nuclear magnetic resonance imaging apparatus and a near-infrared fluorescence imaging apparatus and necrotizing a tumor by a combined photothermal-photodynamic effect.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: April 13, 2021
    Assignee: GWANGJU INSTITUTE OE SCIENCE AND TECHNOLOGY
    Inventors: Giyoong Tae, Abhishek Sahu, Jong Hyun Lee
  • Patent number: 10954348
    Abstract: The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 23, 2021
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Jeongsoo Yoo, Woonghee Lee
  • Patent number: 10945965
    Abstract: The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with a hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal's intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: March 16, 2021
    Assignee: NANOBIOTIX
    Inventors: Agnes Pottier, Laurent Levy, Marie-Edith Meyre
  • Patent number: 10940118
    Abstract: The present disclosure provides methods and compositions related to nanoparticles comprising an encapsulated hydrophobic drug. The methods described herein provide nanoparticles having a small size and a narrow size distribution.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 9, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ying Liu, Zaijie Wang
  • Patent number: 10876197
    Abstract: A composition of matter includes a substrate material (M) having a bulk portion and an outer surface integrated to the bulk portion. The outer surface includes a modified surface layer. The modified surface layer extends to a depth from the outer surface of at least 1 nm. The modified surface layer includes M and at least one other material (X) which is a metal or metal alloy. The modified surface layer has a 25° C. electrical conductivity which is at least 2.5% above or below a 25° C. electrical conductivity in the bulk portion of M. The composition of matter can be an article that includes a frequency selective surface-based metamaterial, and the plurality of modified surface portions can be a plurality of periodic surface elements that provide a resonant frequency.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Aravinda Kar, Rajan Vaidyanathan